Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice
- 12 May 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 36 (8), 1570-1577
- https://doi.org/10.1124/dmd.108.020735
Abstract
Gemcitabine (2′,2′-difluorodeoxyribofuranosylcytosine; dFdC) is an anticancer nucleoside analog active against wide variety of solid tumors. However, this compound is rapidly inactivated by enzymatic deamination and can also induce drug resistance. To overcome the above drawbacks, we recently designed a new squalenoyl nanomedicine of dFdC [4-(N)-trisnorsqualenoyl-gemcitabine (SQdFdC)] by covalently coupling gemcitabine with the 1,1′,2-trisnorsqualenic acid; the resultant nanomedicine displayed impressively greater anticancer activity compared with the parent drug in an experimental murine model. In the present study, we report that SQdFdC nanoassemblies triggered controlled and prolonged release of dFdC and displayed considerably greater t1/2 (∼3.9-fold), mean residence time (∼7.5-fold) compared with the dFdC administered as a free drug in mice. It was also observed that the linkage of gemcitabine to the 1,1′,2-trisnorsqualenic acid noticeably delayed the metabolism of dFdC into its inactive difluorodeoxyuridine (dFdU) metabolite, compared with dFdC. Additionally, the elimination of SQdFdC nanoassemblies was considerably lower compared with free dFdC, as indicated by lower radioactivity found in urine and kidneys, in accordance with the plasmatic concentrations of dFdU. SQdFdC nanoassemblies also underwent considerably higher distribution to the organs of the reticuloendothelial system, such as spleen and liver (p < 0.05), both after single- or multiple-dose administration schedule. Herein, this paper brings comprehensive pharmacokinetic and biodistribution insights that may explain the previously observed greater efficacy of SQdFdC nanoassemblies against experimental leukemia.Keywords
This publication has 16 references indexed in Scilit:
- Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer NanomedicineThe Journal of pharmacology and experimental therapeutics, 2008
- Discovery of New Hexagonal Supramolecular Nanostructures Formed by Squalenoylation of an Anticancer Nucleoside AnalogueSmall, 2008
- Characterization of Lipophilic Gemcitabine Prodrug−Liposomal Membrane Interaction by Differential Scanning CalorimetryMolecular Pharmaceutics, 2006
- Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissuesExperimental Cell Research, 2005
- Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancerJournal of Zhejiang University-SCIENCE B, 2005
- Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugsJournal of Controlled Release, 2004
- Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid TumorsJournal of Clinical Oncology, 2004
- Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometryJournal of Chromatography B, 2004
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Cell cycle effects of gemcitabineInternational Journal of Cancer, 2001